Beyond the PSA: How Proclarix Is Supporting Smarter Clinical Decisions - Episode 2

In this episode, Sidney Ocanagil-Tunstall continues the conversation with Dr Asif Naseem, GP and specialist in preventative healthcare and men's health, and Dr Beat Rheiner, CEO of Proteomedix, this time turning to what a better diagnostic pathway could actually look like in practice.Building on the challenges of PSA testing explored in Episode 1, the discussion moves into the role of emerging tools like Proclarix in supporting smarter clinical decision-making. Asif shares his real-world experience using Proclarix as a private GP, including how it has helped him identify patients who may benefit from further investigation, and those who can safely avoid unnecessary downstream procedures.The conversation broadens into a wider discussion around diagnostics implementation and adoption,  exploring the relationship between laboratory and clinician as part of the same clinical decision-making process, and why awareness of such diagnostic tools remains one of the most important barriers to overcome. As Asif puts it: new tools need to be more accessible, more widely understood, and correctly used.Proclarix is a blood-based test which works in the PSA "grey zone" of 2-10ng/ML to better stratify risk of clinically significant prostate cancer.